GRAIL, Inc., a healthcare company whose mission is to detect cancer early when it can be cured, and Quest Diagnostics, a leading provider of diagnostic information services, today announced the initial phase of a program to improve provider access to GRAIL's Galleri® multi-cancer early detection (MCED) test.

。

Providers can now order the Galleri test directly from GRAIL through the Quest Diagnostics connectivity system. The Quest Diagnostics connectivity system enables providers in the United States to order and receive reports of laboratory tests electronically through Quest's Quanum laboratory portal and more than 900 electronic health record (EHR) systems.

提供者现在可以通过Quest Diagnostics连接系统直接从GRAIL订购Galleri测试。Quest诊断连接系统使美国的供应商能够通过Quest的Quanum实验室门户和900多个电子健康记录（EHR）系统以电子方式订购和接收实验室测试报告。

More than 500,000 providers used the Quest connectivity system last year..

去年，超过500000家提供商使用了Quest连接系统。。

The integration will help streamline the process of ordering the Galleri test for physicians. It will also increase availability by allowing patients access to the test at any of Quest's approximately 7,400 patient access points nationwide. Patients with a test order from their physician can now go directly to Quest without needing to bring a Galleri test kit to the blood draw appointment..

整合将有助于简化为医生订购Galleri测试的过程。。拥有医生测试命令的患者现在可以直接前往Quest，无需携带Galleri测试试剂盒参加抽血预约。。

'Quest Diagnostics and GRAIL share a commitment to improving access to cancer screening and have worked productively together to enable patient access to GRAIL's Galleri test via Quest's phlebotomy network since 2021,' said Mark Gardner, Senior Vice President, Molecular Genomics and Oncology for Quest Diagnostics.

Quest Diagnostics的分子基因组学和肿瘤学高级副总裁马克·加德纳（Mark Gardner）说：“Quest Diagnostics和GRAIL共同致力于改善癌症筛查的机会，自2021年以来，他们一直卓有成效地合作，使患者能够通过Quest的静脉切开术网络获得GRAIL的Galleri检测。”。

'Integrating GRAIL's Galleri test into the Quest connectivity system is the next step in this collaboration. We expect it to increase patient access by giving Quest's provider clients the ability to seamlessly order the test through Quest, same as they do for other blood work. This collaboration brings to life the tremendous value of Quest's ability to scale diagnostic innovation to make it accessible for all.'.

“将GRAIL的Galleri测试集成到Quest连接系统是此次合作的下一步。我们希望它能够通过让Quest的提供者客户能够像其他血液工作一样，通过Quest无缝订购测试，从而增加患者的访问。这种合作为Quest扩展诊断创新的能力带来了巨大的价值，使所有人都可以访问它。”。

Cancers growing in the body shed DNA into the bloodstream. These DNA fragments act like a unique 'fingerprint' of cancer. With a single blood draw, the Galleri test screens for the 'fingerprint' of many of the deadliest cancers before they become symptomatic, including those with no recommended screening tests today.

体内生长的癌症将DNA释放到血液中。这些DNA片段就像癌症的独特“指纹”。通过一次抽血，Galleri测试可以在许多最致命的癌症出现症状之前筛选出“指纹”，包括那些今天没有推荐筛查测试的癌症。

It can also provide doctors with information on the cancer's origin to help predict the tissue type or organ associated with the cancer signal. The Galleri test is prescription only, recommended for adults with an elevated risk for cancer, such as those age 50 or older, and is to be used in addition to recommended cancer screenings..

。Galleri测试仅为处方，建议用于癌症风险较高的成年人，如50岁或以上的成年人，除推荐的癌症筛查外，还应使用。。

'We know every minute counts for busy providers, their staff and their patients, which is why we're so pleased to work with Quest to offer a seamless experience that fits into providers' existing ordering process,' said Josh Ofman, MD, MSHS, President at GRAIL. 'While today there are recommended screenings for five cancers, nearly 70% of deaths are caused by cancers with no recommended screening test.

GRAIL总裁、医学博士、MSHS的乔什·奥夫曼（JoshOfman）说：“我们知道忙碌的供应商、他们的员工和患者每一分钟都很重要，这就是为什么我们很高兴与Quest合作，提供无缝体验，以适应供应商现有的订购流程。”虽然今天有五种癌症的推荐筛查，但近70%的死亡是由没有推荐筛查测试的癌症引起的。

We believe this integration will help to make it easier to incorporate the Galleri test into routine exams to help screen for cancer before it becomes symptomatic when outcomes may be improved.'.

我们相信这种整合将有助于更容易地将Galleri测试纳入常规检查，以帮助在癌症出现症状之前筛查癌症，从而改善预后。”。

About Quest Diagnostics

关于Quest Diagnostics

Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management.

Quest Diagnostics在整个医疗保健生态系统中工作，以创建一个更健康的世界，一次一个生命。我们从实验室检测结果中提供诊断见解，使人们、医生和组织能够采取行动改善健康状况。Quest的诊断见解源自世界上最大的不可识别临床实验室结果数据库之一，揭示了识别和治疗疾病，激发健康行为和改善医疗保健管理的新途径。

Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our more than 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world.

Quest Diagnostics每年为三分之一的成年美国人和美国一半的医生和医院提供服务，我们的55000多名员工明白，在正确的手中和正确的背景下，我们的诊断见解可以激发行动，改变生活，创造一个更健康的世界。

www.QuestDiagnostics.com..

www.QuestDiagnostics.com。

About GRAIL

关于GRAIL

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages.

GRAIL是一家医疗保健公司，其使命是在癌症可以治愈的时候尽早发现癌症。GRAIL专注于通过利用下一代测序，人口规模临床研究以及最先进的机器学习，软件和自动化的力量来减轻全球癌症负担，以在早期阶段检测和识别多种致命癌症类型。

GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom..

GRAIL基于靶向甲基化的平台可以支持筛查和精确肿瘤学的连续护理，包括有症状患者的多种癌症早期检测，风险分层，最小残留疾病检测，生物标志物亚型分析，治疗和复发监测。GRAIL总部位于加利福尼亚州门洛帕克，位于华盛顿特区，北卡罗莱纳州和英国。。

For more information, visit grail.com.

有关更多信息，请访问grail.com。

About Galleri®

关于Galleri®

The Galleri multi-cancer early detection test is a proactive tool to screen for cancer. With a simple blood draw, the Galleri test can identify DNA shed by cancer cells, which can act as a unique 'fingerprint' of cancer, to help screen for some of the deadliest cancers that don't have recommended screening today, such as pancreatic, esophageal, ovarian, liver, and others.* The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable.

Galleri多癌症早期检测测试是筛查癌症的主动工具。通过简单的抽血，Galleri测试可以识别癌细胞脱落的DNA，它可以作为癌症的独特“指纹”，帮助筛查一些目前不建议筛查的致命癌症，如胰腺癌、食道癌、卵巢癌、肝癌等。*Galleri测试可用于在一个人出现症状之前筛查癌症，此时癌症可能更容易治疗并可能治愈。

The Galleri test can indicate the origin of the cancer, giving healthcare providers a roadmap of where to explore further. The Galleri test requires a prescription from a licensed healthcare provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test, or cervical cancer screening.

Galleri测试可以指出癌症的起源，为医疗保健提供者提供进一步探索的路线图。Galleri测试需要获得许可的医疗保健提供者的处方，除了推荐的癌症筛查（如乳房X光检查，结肠镜检查，前列腺特异性抗原（PSA）测试或宫颈癌筛查）外，还应使用该测试。

The Galleri test is recommended for adults with an elevated risk for cancer, such as those aged 50 or older..

Galleri测试建议用于癌症风险较高的成年人，例如50岁或以上的成年人。。

For more information, visit galleri.com.

有关更多信息，请访问galleri.com。

Sensitivity in study participants with –

Pancreas cancer: 83.7% overall (61.9% stage I, 60.0% stage II, 85.7% stage III, 95.9% stage IV). Esophagus cancer 85.0% overall (12.5% stage I, 64.7% stage II, 94.7% stage III, 100% stage IV). Ovary cancer: 83.1% overall (50.0% stage I, 80.0% stage II, 87.1% stage III, 94.7% stage IV). Liver/bile duct cancer: 93.5% overall (100% stage I, 70.0% stage II, 100% stage III, 100% stage IV)..

胰腺癌：总体为83.7%（I期61.9%，II期60.0%，III期85.7%，IV期95.9%）。食管癌总体为85.0%（I期12.5%，II期64.7%，III期94.7%，IV期100%）。卵巢癌：总体为83.1%（I期50.0%，II期80.0%，III期87.1%，IV期94.7%）。肝/胆管癌：总体为93.5%（I期100%，II期70.0%，III期100%，IV期100%）。。

Important Galleri Safety Information

重要的Galleri安全信息

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located.

Galleri测试建议用于癌症风险较高的成年人，例如50岁或以上的成年人。Galleri测试不能检测所有癌症，除了医疗保健提供者推荐的常规癌症筛查测试外，还应使用该测试。Galleri旨在检测癌症信号并预测癌症信号在体内的位置。

Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment..

怀孕、21岁或以下或正在接受积极癌症治疗的个体不建议使用Galleri。。

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g.

结果应由医疗保健提供者根据病史，临床体征和症状进行解释。没有检测到癌症信号的测试结果并不排除癌症。检测到的癌症信号的测试结果需要通过医学上建立的程序（例如。

imaging) to confirm cancer..

成像）以确认癌症。。

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur.

如果癌症没有通过进一步的检测得到证实，则可能意味着癌症不存在或检测不足以检测癌症，包括由于癌症位于身体的不同部位。确实会出现假阳性（不存在癌症时检测到癌症信号）和假阴性（存在癌症时未检测到癌症信号）测试结果。

Rx only..

仅接收。。

Laboratory/Test Information

实验室/测试信息

The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration.

GRAIL临床实验室通过了1988年临床实验室改进修正案（CLIA）的认证，并获得了美国病理学家学院的认可。开发了Galleri测试，并通过GRAIL确定了其性能特征。加莱里试验尚未获得食品和药物管理局的批准或批准。

The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes..

GRAIL临床实验室受CLIA监管，以执行高复杂性测试。Galleri测试旨在用于临床目的。。

GRAIL Forward Looking Statements

GRAIL前瞻性声明

This press release contains forward-looking statements. In some cases, you can identify these statements by forward-looking words such as 'aim,' 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'should,' 'would,' or 'will,' the negative of these terms, and other comparable terminology.

本新闻稿包含前瞻性声明。在某些情况下，你可以通过前瞻性的词语来识别这些陈述，例如“目标”、“预期”、“相信”、“继续”、“可能”、“估计”、“预期”、“打算”、“可能”、“可能”、“计划”、“潜力”、“预测”、“应该”、“将会”或“将会”，这些术语的否定词以及其他类似术语。

These forward-looking statements, which are subject to risks, uncertainties, and assumptions about us, may include statements about benefits of the integration between the Quest connectivity system and Galleri..

这些前瞻性声明可能包括关于Quest connectivity system和Galleri之间集成的好处的声明，这些声明受到我们的风险、不确定性和假设的影响。。

These statements are only predictions based on GRAIL's current expectations and projections about future events and trends. There are important factors that could cause our actual results, level of activity, performance, or achievements to differ materially and adversely from those expressed or implied by the forward-looking statements, including those factors discussed under the section entitled 'Risk Factors' in GRAIL's most recent Quarterly Report on Form 10-Q filed with the SEC.

这些声明只是根据圣杯当前对未来事件和趋势的预期和预测做出的预测。有一些重要因素可能会导致我们的实际业绩、活动水平、绩效或成就与前瞻性声明中明示或暗示的结果、活动水平、绩效或成就产生重大不利差异，包括GRAIL最近提交给SEC的10-Q表季度报告中题为“风险因素”一节中讨论的因素。

Moreover, GRAIL operates in a dynamic and rapidly changing environment. New risks emerge from time to time. It is not possible for GRAIL's management to predict all risks, nor can they assess the impact of all factors on GRAIL's business or the extent to which any factor, or combination of factors, may cause actual results, level of activity, performance, or achievements to differ materially and adversely from those contained in any forward-looking statements GRAIL may make..

此外，GRAIL在一个动态且快速变化的环境中运行。新的风险不时出现。GRAIL的管理层不可能预测所有风险，也不可能评估所有因素对GRAIL业务的影响，也不可能评估任何因素或因素组合可能导致实际结果、活动水平、绩效或成就与GRAIL可能做出的任何前瞻性声明中所载的结果、活动水平、绩效或成就产生重大不利影响的程度。。

Forward-looking statements relate to the future and, accordingly, are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of GRAIL's control. Although GRAIL believes the expectations and projections expressed or implied by the forward-looking statements are reasonable, GRAIL cannot guarantee future results, level of activity, performance, or achievements.

前瞻性陈述与未来有关，因此会受到难以预测的固有不确定性、风险和环境变化的影响，其中许多不在GRAIL的控制范围之内。尽管GRAIL认为前瞻性声明所表达或暗示的期望和预测是合理的，但GRAIL无法保证未来的结果、活动水平、绩效或成就。

GRAIL's actual results and financial condition may differ materially from those indicated in the forward-looking statements. Except to the extent required by law, GRAIL undertakes no obligation to update any of these forward-looking statements after the date of this press release to conform its prior statements to actual results or revised expectations or to reflect new information or the occurrence of unanticipated events..

圣杯的实际业绩和财务状况可能与前瞻性报表中显示的结果和财务状况存在重大差异。除法律要求外，GRAIL没有义务在本新闻稿发布之日后更新任何前瞻性声明，以使其先前的声明符合实际结果或修订后的预期，或反映新信息或意外事件的发生。。

Source: prnewswire.com

来源：prnewswire.com